Clinical trial
A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)
NCT01539590 is registered in ClinicalTrials.gov with Angion Biomedica Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)
- Lead sponsor
- Angion Biomedica Corp
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 31, 2012
- Completion date
- November 30, 2013
- Enrollment
- 5 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.